Sean Maduck - Mar 27, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Stock symbol
CORT
Transactions as of
Mar 27, 2024
Transactions value $
-$548,327
Form type
4
Date filed
3/29/2024, 02:12 PM
Previous filing
Mar 20, 2024
Next filing
May 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $101K +26K +30.45% $3.88* 111K Mar 27, 2024 Direct F1
transaction CORT Common Stock Sale -$649K -26K -23.34% $25.01 85.2K Mar 27, 2024 Direct F1, F2
holding CORT Common Stock 10K Mar 27, 2024 See Footnote F3
holding CORT Common Stock 10K Mar 27, 2024 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -26K -22.01% $0.00 92K Mar 27, 2024 Common Stock 26K $3.88 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
F3 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F4 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F5 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.